Skip to main content
Book cover

Encyclopedia of Child Behavior and Development pp 2–3Cite as

Abilify

  • Reference work entry

  • 549 Accesses

Synonyms

Aripiprazole (generic name); Atypical antipsychotics; Partial dopamine agonist

Definition

Abilify (Abilify) is an atypical antipsychotic medication indicated for acute and maintenance treatment of adult as well as adolescent (13–17 years of age) patients with Schizophrenia. The medication also is indicated for acute and maintenance treatment of manic and mixed episodes associated with Bipolar I Disorder with or without psychotic features in adult and pediatric (10–17 years of age) patients [1].

Description

Abilify was developed by Otsuka Pharmaceutical in Japan and jointly marketed in the United States with Bristol-Myers Squibb [1]. Clinical trials sponsored by the manufacturer have resulted in the Food and Drug Administration (FDA) approving the use of Abilify as an atypical antipsychotic [1–3]. The FDA first approved Abilify for the treatment of adult Schizophrenia in November, 2002. The medication received additional approval by the FDA for the acute and maintenance...

This is a preview of subscription content, access via your institution.

Chapter
USD   29.95
Price excludes VAT (USA)
  • DOI: 10.1007/978-0-387-79061-9_11
  • Chapter length: 2 pages
  • Instant PDF download
  • Readable on all devices
  • Own it forever
  • Exclusive offer for individuals only
  • Tax calculation will be finalised during checkout
eBook
USD   949.00
Price excludes VAT (USA)
  • ISBN: 978-0-387-79061-9
  • Instant PDF download
  • Readable on all devices
  • Own it forever
  • Exclusive offer for individuals only
  • Tax calculation will be finalised during checkout
Hardcover Book
USD   999.99
Price excludes VAT (USA)
Learn about institutional subscriptions

References

  1. Bowles, T. M., & Levin, G. M. (2003). Aripiprazole: A new atypical antipsychotic drug. Annals of Pharmacotherapy, 37, 187–194.

    Google Scholar 

  2. Bristol-Meyers Squibb Company. (2008). Abilify prescribing information. Princeton, NJ: Bristol-Meyers Squibb Company.

    Google Scholar 

  3. DeLeon, A. (2004). Aripiprazole: A comprehensive review of its pharmacology, clinical efficacy, and tolerability. Clinical Therapeutics, 26(5), 649–666.

    PubMed  Google Scholar 

  4. Hammad, T. A., Laughren, T. P., & Racoosin, J. A. (2006). Suicidality in pediatric patients treated with antidepressant drugs. Archives of General Psychiatry, 63(3), 332–339.

    PubMed  Google Scholar 

  5. Lawler, C. P., Prioleau, C., Lewis, M. M., Mak, C., Jiang, D., Schetz, J. A., et al. (1999). Interactions of the novel antipsychotic aripiprazole (OPC-14597) with dopamine and serotonin receptor subtypes. Neuropsychopharmacology, 20(6), 612–627.

    PubMed  Google Scholar 

  6. Mottola, D. M., Kilts, J. D., Lewis, M. M., Connery, J. S., Walker, Q. D., & Jones, S. R. (2002). Functional selectivity of dopamine receptor agonists. I. selective activation of postsynaptic dopamine D2 receptors linked to adenylate cyclase. The Journal of Pharmacology and Experimental Therapeutics, 301(3), 1166–1178.

    PubMed  Google Scholar 

  7. Rugino, T. A., & Janvier, Y. M. (2005). Aripiprazole in children and adolescents: Clinical experience. Journal of Child Neurology, 20(7), 603–610.

    PubMed  Google Scholar 

  8. Seifert, S. A., Schwartz, M. D., & Thomas, J. D. (2005). Aripiprazole (Abilify) overdose in a child. Clinical Toxicology, 43, 193–195.

    PubMed  Google Scholar 

  9. Shapiro, D. A., Renock, S., Arrington, E., Louis, A. C., Li-Xin, L., Sibley, D. R., et al. (2003). Abilify, a novel atypical antipsychotic drug with a unique and robust pharmacology. Neuropsychopharmacology, 28, 1400–1411.

    PubMed  Google Scholar 

  10. Stark, A. D., Jordan, S., Allers, K. A., Bertekap, R. L., Chen, R., & Kannan, T. M. (2007). Interaction of the novel antipsychotic Abilify with 5-HT1A and 5-HT2A receptors: Functional receptor-binding and in vivo electrophysiological studies. Psychopharmacology, 190, 373–382.

    PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Educational Psychology, Ball State University, Teachers College Room 515, Muncie, IN, 47306, USA

    Jeffrey S. Trotter

  2. Department of Educational Psychology, Ball State University, Teachers College Room 515, Muncie, IN, 47306, USA

    Andrew S. Davis

Authors
  1. Jeffrey S. Trotter
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Andrew S. Davis
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. Neurology, Learning and Behavior Center, 230 South 500 East, Suite 100, Salt Lake City, Utah, 84102, USA

    Sam Goldstein Ph.D.

  2. Professor of Psychology, Department of Psychology MS 2C6, George Mason University, Fairfax, VA, 22030, USA

    Jack A. Naglieri Ph.D.

Rights and permissions

Reprints and Permissions

Copyright information

© 2011 Springer Science+Business Media, LLC

About this entry

Cite this entry

Trotter, J.S., Davis, A.S. (2011). Abilify. In: Goldstein, S., Naglieri, J.A. (eds) Encyclopedia of Child Behavior and Development. Springer, Boston, MA. https://doi.org/10.1007/978-0-387-79061-9_11

Download citation